AR107042A1 - Inhibidores de la tirosina quinasa de bruton y métodos de su uso - Google Patents
Inhibidores de la tirosina quinasa de bruton y métodos de su usoInfo
- Publication number
- AR107042A1 AR107042A1 ARP160103789A ARP160103789A AR107042A1 AR 107042 A1 AR107042 A1 AR 107042A1 AR P160103789 A ARP160103789 A AR P160103789A AR P160103789 A ARP160103789 A AR P160103789A AR 107042 A1 AR107042 A1 AR 107042A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- haloalkyl
- phenyl
- optionally substituted
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract 3
- 125000004076 pyridyl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229960002685 biotin Drugs 0.000 abstract 1
- 239000011616 biotin Substances 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente descripción se refiere a compuestos, a métodos para su uso y preparación, así como a composiciones que los comprenden. Reivindicación 1: Un compuesto de la fórmula (1), en donde R¹ es H; R² se selecciona del grupo que consiste en: CH₂-ciclohexilo, en donde el ciclohexilo se sustituye opcionalmente con OH; 3-hidroxiadamantan-1-ilo; y cicloalquilo C₃₋₆ sustituido opcionalmente con 1, 2 ó 3 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en: OH, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, O-alquilo C₁₋₆, CN, NR⁶R⁷, NR⁸-C(O)H, NR⁸-C(O)-alquilo C₁₋₆, NR⁸-C(O)-haloalquilo C₁₋₆, NR⁸-C(O)-O-alquilo C₁₋₆, NR⁸-C(O)-alq C₁₋₆-OH, NR⁸-C(O)-alq C₁₋₆-NR⁶R⁷ y NR⁸-C(O)-C(R³)=CR⁴(R⁵); en donde R³ se selecciona del grupo que consiste en: H, CN, halógeno, haloalquilo C₁₋₆ y alquilo C₁₋₆; R⁴ y R⁵ se seleccionan, independientemente cada uno, del grupo que consiste en: H; alq C₀₋₆-NR⁶R⁷; alq C₁₋₆-O-alquilo C₁₋₆; cicloalquilo C₃₋₆; heterocicloalquilo sustituido opcionalmente con alquilo C₁₋₆; y enlazador-PEG-biotina; R⁶ y R⁷ se seleccionan, independientemente cada uno, del grupo que consiste en: H, alquilo C₁₋₆, C₍O₎H ʸ CN; ʸ R⁸ es H; o R¹ y R², conjuntamente con el átomo de nitrógeno al que están unidos, forman un anillo de pirrolidinilo sustituido opcionalmente con NR⁶R⁷, en donde R⁶ y R⁷ se seleccionan, independientemente cada uno, del grupo que consiste en H; alquilo C₁₋₆; NR⁸-C(O)-alquilo C₁₋₆; y NR⁸-C(O)-C(R³)=CR⁴(R⁵), en donde R³ es H o CN; R⁴ es H; y R⁵ es H o ciclopropilo; A se selecciona del grupo que consiste en: piridilo; fenilo; pirimidinilo; pirazinilo; piridin-2(1H)-ona; y piridazinilo; en donde A se sustituye opcionalmente con 1, 2 ó 3 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆ y O-alquilo C₁₋₆; E se selecciona del grupo que consiste en: O, un enlace y CH₂; G se selecciona del grupo que consiste en: H; halógeno; alquilo C₁₋₆; haloalquilo C₁₋₆; NH(alquilo C₁₋₆); cicloalquilo C₃₋₆; fenilo; pirimidinilo; piridilo; piridazinilo; piridin-2(1H)-ona; heterocicloalquilo que contiene un heteroátomo de oxígeno; y fenil-CH₂-O-fenilo, en donde -O-fenilo se sustituye con CN; en donde el fenilo; piridilo; piridazinilo; y piridin-2(1H)-ona se sustituyen opcionalmente con 1, 2 ó 3 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en: halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, O-haloalquilo C₁₋₆ y O-alquilo C₁₋₆; y estereoisómeros y variantes isotópicas de estos; y sales farmacéuticamente aceptables de estos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265836P | 2015-12-10 | 2015-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107042A1 true AR107042A1 (es) | 2018-03-14 |
Family
ID=57681784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103789A AR107042A1 (es) | 2015-12-10 | 2016-12-12 | Inhibidores de la tirosina quinasa de bruton y métodos de su uso |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10717745B2 (es) |
| EP (2) | EP3719022A1 (es) |
| JP (2) | JP6835846B2 (es) |
| KR (1) | KR102103395B1 (es) |
| CN (2) | CN113121562B (es) |
| AR (1) | AR107042A1 (es) |
| AU (1) | AU2016366541B2 (es) |
| BR (1) | BR112018011526B1 (es) |
| CA (1) | CA3007990C (es) |
| CY (1) | CY1123263T1 (es) |
| DK (1) | DK3386991T3 (es) |
| EA (1) | EA035168B1 (es) |
| ES (1) | ES2805835T3 (es) |
| HR (1) | HRP20201193T1 (es) |
| HU (1) | HUE049502T2 (es) |
| IL (1) | IL259863B (es) |
| JO (1) | JO3794B1 (es) |
| LT (1) | LT3386991T (es) |
| MA (2) | MA43409B1 (es) |
| MD (1) | MD3386991T2 (es) |
| ME (1) | ME03803B (es) |
| MX (1) | MX387590B (es) |
| PL (1) | PL3386991T3 (es) |
| PT (1) | PT3386991T (es) |
| RS (1) | RS60604B1 (es) |
| SI (1) | SI3386991T1 (es) |
| SM (1) | SMT202000404T1 (es) |
| TW (1) | TWI729047B (es) |
| UY (1) | UY37015A (es) |
| WO (1) | WO2017100662A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US20200079790A1 (en) * | 2017-03-15 | 2020-03-12 | Janssen Sciences Ireland Unlimited Company | Methods of selective aryl- and heteroaryl-nitrogen bond formation |
| CN108164397B (zh) * | 2018-01-18 | 2020-11-13 | 暨南大学 | 一类邻苯二酚衍生物及其制备方法 |
| JP7357644B2 (ja) | 2018-06-11 | 2023-10-06 | アムジエン・インコーポレーテツド | がんを処置するためのｋｒａｓ ｇ１２ｃ阻害剤 |
| ES2949871T3 (es) | 2019-04-11 | 2023-10-03 | Janssen Pharmaceutica Nv | Anillos de piridina que contienen derivados como inhibidores de MALT1 |
| WO2021139717A1 (zh) * | 2020-01-07 | 2021-07-15 | 南京明德新药研发有限公司 | 氘代噻吩并吡啶类化合物 |
| WO2022184716A1 (en) | 2021-03-03 | 2022-09-09 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| BR112023025459A2 (pt) | 2021-06-04 | 2024-02-27 | Janssen Pharmaceutica Nv | Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos |
| AU2022305095A1 (en) | 2021-06-30 | 2024-02-15 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| MX2024001840A (es) | 2021-08-09 | 2024-02-28 | Janssen Pharmaceutica Nv | Composiciones para usar en el tratamiento de neoplasias de celulas b. |
| IL314902A (en) * | 2022-02-18 | 2024-10-01 | Janssen Pharmaceutica Nv | Synthesis of bruton's tyrosine kinase inhibitors |
| WO2025262118A1 (en) | 2024-06-20 | 2025-12-26 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3112415A1 (de) | 1981-03-28 | 1982-10-07 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden |
| US5430150A (en) | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
| US5300478A (en) | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
| JP2008513463A (ja) | 2004-09-15 | 2008-05-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チアゾロピリジンキナーゼ阻害剤 |
| WO2006118749A1 (en) * | 2005-05-04 | 2006-11-09 | Janssen Pharmaceutica, N.V. | Thia-tetraazaacenaphthylene kinase inhibitors |
| AU2006278627B2 (en) | 2005-08-08 | 2011-08-18 | Janssen Pharmaceutica, N.V. | Thiazolopyrimidine kinase inhibitors |
| US7427625B2 (en) * | 2006-02-08 | 2008-09-23 | Janssen Pharmaceutica, N.V. | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| US8598174B2 (en) * | 2008-11-12 | 2013-12-03 | Genetech, Inc. | Pyridazinones, method of making, and method of use thereof |
| EP2471789B9 (en) * | 2009-08-26 | 2015-03-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| WO2011133609A2 (en) | 2010-04-19 | 2011-10-27 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of btk inhibitors |
| FR2978441A1 (fr) | 2011-07-25 | 2013-02-01 | Diverchim | Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques |
| CN105026400A (zh) | 2013-03-15 | 2015-11-04 | 詹森药业有限公司 | 用于制备药物的方法和中间体 |
| AR098721A1 (es) * | 2013-12-11 | 2016-06-08 | Biogen Idec Inc | Inhibidores de biarilo de tirosina quinasa de bruton |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| WO2018103058A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| WO2018103060A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2016
- 2016-12-08 JO JOP/2016/0256A patent/JO3794B1/ar active
- 2016-12-09 BR BR112018011526-6A patent/BR112018011526B1/pt active IP Right Grant
- 2016-12-09 MA MA43409A patent/MA43409B1/fr unknown
- 2016-12-09 US US15/374,905 patent/US10717745B2/en active Active
- 2016-12-09 MA MA053110A patent/MA53110A/fr unknown
- 2016-12-09 EP EP20177012.0A patent/EP3719022A1/en active Pending
- 2016-12-09 EP EP16820106.9A patent/EP3386991B1/en active Active
- 2016-12-09 ME MEP-2020-155A patent/ME03803B/me unknown
- 2016-12-09 AU AU2016366541A patent/AU2016366541B2/en active Active
- 2016-12-09 PT PT168201069T patent/PT3386991T/pt unknown
- 2016-12-09 MD MDE20180978T patent/MD3386991T2/ro unknown
- 2016-12-09 DK DK16820106.9T patent/DK3386991T3/da active
- 2016-12-09 UY UY0001037015A patent/UY37015A/es active IP Right Grant
- 2016-12-09 EA EA201891378A patent/EA035168B1/ru unknown
- 2016-12-09 KR KR1020187018900A patent/KR102103395B1/ko active Active
- 2016-12-09 PL PL16820106T patent/PL3386991T3/pl unknown
- 2016-12-09 SM SM20200404T patent/SMT202000404T1/it unknown
- 2016-12-09 RS RS20200884A patent/RS60604B1/sr unknown
- 2016-12-09 JP JP2018530000A patent/JP6835846B2/ja active Active
- 2016-12-09 CN CN202110404024.3A patent/CN113121562B/zh active Active
- 2016-12-09 HU HUE16820106A patent/HUE049502T2/hu unknown
- 2016-12-09 CN CN201680072125.2A patent/CN108884106A/zh active Pending
- 2016-12-09 ES ES16820106T patent/ES2805835T3/es active Active
- 2016-12-09 TW TW105140760A patent/TWI729047B/zh active
- 2016-12-09 LT LTEP16820106.9T patent/LT3386991T/lt unknown
- 2016-12-09 MX MX2018007075A patent/MX387590B/es unknown
- 2016-12-09 HR HRP20201193TT patent/HRP20201193T1/hr unknown
- 2016-12-09 CA CA3007990A patent/CA3007990C/en active Active
- 2016-12-09 WO PCT/US2016/065954 patent/WO2017100662A1/en not_active Ceased
- 2016-12-09 SI SI201630825T patent/SI3386991T1/sl unknown
- 2016-12-12 AR ARP160103789A patent/AR107042A1/es active IP Right Grant
-
2018
- 2018-06-07 IL IL259863A patent/IL259863B/en active IP Right Grant
-
2019
- 2019-05-15 US US16/413,453 patent/US10934310B2/en active Active
-
2020
- 2020-05-13 US US15/931,437 patent/US11319329B2/en active Active
- 2020-08-18 CY CY20201100769T patent/CY1123263T1/el unknown
-
2021
- 2021-02-04 JP JP2021016602A patent/JP7072690B2/ja active Active
-
2022
- 2022-03-25 US US17/705,225 patent/US12065446B2/en active Active
-
2024
- 2024-07-03 US US18/763,484 patent/US20240383914A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR109805A1 (es) | Derivados de oxadiazol microbiocidas | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR097431A1 (es) | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim | |
| AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR110405A1 (es) | Compuestos | |
| AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR106099A1 (es) | Compuestos bicíclicos como inhibidores duales de atx / ca | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
| AR107041A1 (es) | Inhibidores de la tirosina kinasa de bruton y métodos de su uso | |
| AR087870A1 (es) | Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina | |
| AR093504A1 (es) | 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR109296A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| AR102825A1 (es) | Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre | |
| AR097756A1 (es) | Derivados de fenilalanina sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |